Covaxin 77.8% Effective In Phase 3 Trial Data: Sources | Read

PUBLISHED ON: June 22, 2021 | Duration: 2 min, 55 sec

  
loading..
Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19, according to data from Phase III trials conducted on 25,800 participants across India. Sources said trial data and results were studied and recommended for approval by the DCGI's Subject Expert Committee on Tuesday. The data was submitted to the DCGI over the weekend.
ALSO WATCH
The Biggest Stories Of August 03, 2021

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com